TrialNature communications2024

A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss.

Anne G M Schilder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.